2023
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
Lin H, Can T, Kahn A, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner R, Pusztai L, Rozenblit M. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. The Oncologist 2023, 28: e973-e976. PMID: 37656608, PMCID: PMC10546821, DOI: 10.1093/oncolo/oyad249.Peer-Reviewed Original ResearchConceptsHER2 mRNA levelsIHC 0MRNA levelsOncotype DX recurrence score resultsEstrogen receptor-positive breast cancerReceptor-positive breast cancerCurrent adjuvant chemotherapyOncotype DX assayRecurrence Score resultsPositive breast cancerInvasive breast carcinomaIHC score 0Adjuvant chemotherapyQuantitative RT-PCRBreast carcinomaPositive statusScore 0Breast cancerStage IYale cohortHigher mRNA levelsCancerRT-PCRPatientsHER2
2015
Contact Dermatitis
Rozenblit M, Guttman‐Yassky E. Contact Dermatitis. 2015, 25-35. DOI: 10.1002/9781118609125.ch3.Peer-Reviewed Original ResearchIrritant contact dermatitisAllergic contact dermatitisContact dermatitisType IV hypersensitivity reactionHypersensitivity reactionsPhysical examinationPatch testingInflammatory reactionDermatitisCommon agentsGlucocorticoid creamWet dressingsSkinDiagnosisTreatmentIndustrial solventsAgentsLichenificationPatientsPrognosisAllergensHyperkeratosesPreventionIdentification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection
Esaki H, Ewald DA, Ungar B, Rozenblit M, Zheng X, Xu H, Estrada YD, Peng X, Mitsui H, Litman T, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. Journal Of Allergy And Clinical Immunology 2015, 135: 153-163. PMID: 25567045, PMCID: PMC4452382, DOI: 10.1016/j.jaci.2014.10.037.Peer-Reviewed Original ResearchConceptsNonlesional AD skinLaser capture microdissectionAD transcriptomeNormal skinAD skinNonlesional skinNovel ImmuneCapture microdissectionAtopic dermatitis lesionsBarrier genesPossible cellular sourcesAtopic dermatitisHealthy volunteersEpidermal alterationsBarrier phenotypeCellular sourceImmune moleculesCellular subsetsDermatitis lesionsImmuneDermal compartmentSkinGenomic profilesPatientsMolecular signatures
2003
Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis
Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2003, 14: 7-16. PMID: 14578093, DOI: 10.1080/jdt.14.s2.7.16.Peer-Reviewed Original ResearchRetrospective study of the efficacy of narrowband UVB and acitretin
Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. PMID: 14578094, DOI: 10.1080/jdt.14.s2.17.20.Peer-Reviewed Original ResearchConceptsCombination of acitretinNarrowband UVBPlaque psoriasisUltraviolet BBroadband ultraviolet BLow-dose acitretinUVB three timesMajority of patientsUltraviolet B treatmentDose acitretinOral acitretinSerum lipidsTreat patientsTreat groupNumber of treatmentsRetrospective studyBroadband UVBRetrospective analysisAcitretinSide effectsUVB resultsPatientsPhototherapy treatmentMonotherapyPsoriasisRetrospective study of the efficacy of narrowband UVB and acitretin
Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. DOI: 10.1080/738528794.Peer-Reviewed Original ResearchConceptsCombination of acitretinNarrowband UVBPlaque psoriasisUltraviolet BBroadband ultraviolet BLow-dose acitretinUVB three timesMajority of patientsUltraviolet B treatmentDose acitretinOral acitretinSerum lipidsTreat patientsTreat groupNumber of treatmentsRetrospective studyBroadband UVBRetrospective analysisAcitretinSide effectsUVB resultsPatientsPhototherapy treatmentMonotherapyPsoriasis
2000
Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis
Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2000, 14: 7-16. DOI: 10.1080/738528793.Peer-Reviewed Original ResearchTransition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis
Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2000, 14: 7-16. DOI: 10.1080/753995509.Peer-Reviewed Original Research